Tianfu Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tianfu Wu has a total of 375 co-authors. Here are the top co-authors by number of shared publications:
Chandra Mohan
University of Houston
30 shared publications- Chandra Mohan
Department Biomedical Engineering, University of Houston, United States
24 shared publications Ramesh Saxena
University of Texas Southwestern Medical Center
11 shared publicationsXin J. Zhou
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA
11 shared publicationsYaxi Li
University of Houston
11 shared publications- Zuan-Tao Lin
University of Houston
11 shared publications
Latest Publications
- 14 October 2026
- Published by SAGE Publications in Lupus
Serum cell adhesion molecules (CAMs) NrCAM and P-Cadherin as novel biomarkers in lupus nephritis
Objective: This study aimed to identify novel serum biomarkers for lupus nephritis (LN) and evaluate their potential for improving diagnosis, monitoring disease activity, and understanding LN pathogenesis. Methods: A cell adhesion molecules (CAMs) antibody microarray was utilized to identify potential biomarkers of LN using serum samples from LN, chronic kidney disease (CKD), and healthy controls (HC). Differential expression analysis and LASSO regression identified CAM biomarkers in a discovery cohort, followed by ELISA validation in an independent, discovery cohort. Biomarker correlations with clinicopathological parameters were assessed, and receiver operating characteristic (ROC) analyses were performed to examine the potential diagnostic utility. Results: Of the 17 CAMs analyzed, serum NrCAM and P-Cadherin emerged as the most promising new biomarkers, significantly discriminating LN from HC. Serum NrCAM was found to differentiate between LN and HC ( p < 0.0001) as well as active LN (LNA) from inactive LN (LNI) ( p < 0.01) in the discovery cohort. Serum P-Cadherin, however, differentiated LN from both HC ( p < 0.0001) and CKD ( p < 0.001) and distinguished LNA from LNI ( p < 0.01). In a larger validation cohort, ROC analyses demonstrated strong diagnostic potential for both biomarkers, with AUC values of 0.92 and 0.82 for serum NrCAM and P-Cadherin, respectively. Significant correlations with SLEDAI, rSLEDAI, and histological indices further underscored their potential relevance to LN severity and activity. Interestingly, serum NrCAM and P-Cadherin are complementary in reflecting renal pathology changes including endocapillary hypercellularity, cellular crescents, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. Conclusion: Serum NrCAM and P-Cadherin show promise as non-invasive biomarkers for LN, offering potential utility in diagnosis and disease monitoring. Their ability to distinguish between disease states and correlate with clinical parameters highlights their potential to improve patient stratification and guide personalized treatment approaches in LN.
- 14 October 2026
- Published by SAGE Publications in Lupus
Serum cell adhesion molecules (CAMs) NrCAM and P-Cadherin as novel biomarkers in lupus nephritis
Objective: This study aimed to identify novel serum biomarkers for lupus nephritis (LN) and evaluate their potential for improving diagnosis, monitoring disease activity, and understanding LN pathogenesis. Methods: A cell adhesion molecules (CAMs) antibody microarray was utilized to identify potential biomarkers of LN using serum samples from LN, chronic kidney disease (CKD), and healthy controls (HC). Differential expression analysis and LASSO regression identified CAM biomarkers in a discovery cohort, followed by ELISA validation in an independent, discovery cohort. Biomarker correlations with clinicopathological parameters were assessed, and receiver operating characteristic (ROC) analyses were performed to examine the potential diagnostic utility. Results: Of the 17 CAMs analyzed, serum NrCAM and P-Cadherin emerged as the most promising new biomarkers, significantly discriminating LN from HC. Serum NrCAM was found to differentiate between LN and HC ( p < 0.0001) as well as active LN (LNA) from inactive LN (LNI) ( p < 0.01) in the discovery cohort. Serum P-Cadherin, however, differentiated LN from both HC ( p < 0.0001) and CKD ( p < 0.001) and distinguished LNA from LNI ( p < 0.01). In a larger validation cohort, ROC analyses demonstrated strong diagnostic potential for both biomarkers, with AUC values of 0.92 and 0.82 for serum NrCAM and P-Cadherin, respectively. Significant correlations with SLEDAI, rSLEDAI, and histological indices further underscored their potential relevance to LN severity and activity. Interestingly, serum NrCAM and P-Cadherin are complementary in reflecting renal pathology changes including endocapillary hypercellularity, cellular crescents, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. Conclusion: Serum NrCAM and P-Cadherin show promise as non-invasive biomarkers for LN, offering potential utility in diagnosis and disease monitoring. Their ability to distinguish between disease states and correlate with clinical parameters highlights their potential to improve patient stratification and guide personalized treatment approaches in LN.
- 5 August 2026
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 12 (9) , 4793-4802
Mannosylated Spleen-Targeted Lipid Nanoparticles Enable Enhanced mRNA Delivery to Antigen-Presenting Cells
Targeted delivery of lipid nanoparticles (LNP) to immune organs remains challenging, and here we introduce a mannosylated spleen-targeted LNP (LNP-PAM) that integrates active and endogenous targeting to enhance mRNA delivery to antigen-presenting cells. A mannose-conjugated fifth lipid (PA-Mannose, PAM) was incorporated into spleen-targeted LNPs at varying molar ratios, followed by a systematic evaluation of physicochemical properties, in vitro transfection, in vivo biodistribution, cellular uptake, and mRNA expression. All formulations exhibited uniform particle size and low polydispersity, and increasing PAM content from 5% to 10% shifted LNP accumulation from the liver to the spleen, ultimately achieving exclusive spleen localization. LNP-PAM showed superior in vitro transfection in macrophages relative to conventional LNPs and higher in vivo mRNA expression in the spleen, with flow cytometry confirming preferential uptake by macrophages and type-2 conventional dendritic cells (cDC2) populations consistent with CD206-mediated endocytosis. The system maintained physicochemical stability after freeze−thaw and demonstrated minimal cytotoxicity. Together, these findings indicate that mannosylation enhances spleen-targeted mRNA delivery through receptor-mediated uptake by macrophages and dendritic cells without compromising formulation robustness, positioning LNP-PAM as a practical platform for selective immune organ delivery and RNA-based immunomodulation.
- 5 August 2026
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 12 (9) , 4793-4802
Mannosylated Spleen-Targeted Lipid Nanoparticles Enable Enhanced mRNA Delivery to Antigen-Presenting Cells
Targeted delivery of lipid nanoparticles (LNP) to immune organs remains challenging, and here we introduce a mannosylated spleen-targeted LNP (LNP-PAM) that integrates active and endogenous targeting to enhance mRNA delivery to antigen-presenting cells. A mannose-conjugated fifth lipid (PA-Mannose, PAM) was incorporated into spleen-targeted LNPs at varying molar ratios, followed by a systematic evaluation of physicochemical properties, in vitro transfection, in vivo biodistribution, cellular uptake, and mRNA expression. All formulations exhibited uniform particle size and low polydispersity, and increasing PAM content from 5% to 10% shifted LNP accumulation from the liver to the spleen, ultimately achieving exclusive spleen localization. LNP-PAM showed superior in vitro transfection in macrophages relative to conventional LNPs and higher in vivo mRNA expression in the spleen, with flow cytometry confirming preferential uptake by macrophages and type-2 conventional dendritic cells (cDC2) populations consistent with CD206-mediated endocytosis. The system maintained physicochemical stability after freeze−thaw and demonstrated minimal cytotoxicity. Together, these findings indicate that mannosylation enhances spleen-targeted mRNA delivery through receptor-mediated uptake by macrophages and dendritic cells without compromising formulation robustness, positioning LNP-PAM as a practical platform for selective immune organ delivery and RNA-based immunomodulation.
- Open Access
- 31 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Immunomodulation of behavior impairment via spleen-specific targeting lipid nanoparticles in a MeCP2 transgenic mouse model
This study investigates a novel approach using spleen-targeting lipid nanoparticles (LNPs) to immunomodulate behavioral impairment in a Methyl-CpG-binding protein 2 (Mecp2) transgenic mouse model. In a human Mecp2 transgenic mouse model (B6.Mecp2Tg1), spleen-targeting lipid nanoparticles encapsulated with antisense oligonucleotides (ASO) were employed as a mitigating agent. Splenic immune cells were analyzed using flow cytometry; autoantibody production was assessed using autoantigen protein microarrays, including a central nervous system (CNS) protein microarray. Furthermore, proinflammatory cytokines, MeCP2-mediated signaling pathways, and manifestations of behavior functions and kidney disease were examined. Our findings indicated a reduction in splenic MeCP2 levels following in vivo knockdown via ASO. Notably, splenic immune cells, including B and T cells, particularly plasma B cells, were significantly reduced after LNP-ASO treatment. Levels of autoantibodies against typical nuclear antigens such as Sm, U1-snRNP B/B, and nucleosome antigens, as well as brain antigens including OLIG2, GAD2, GJA1, and YWHAE, were significantly alleviated. Proinflammatory molecules such as IL-5, TNF-α, CCL20 and TGF-β1 showed significant reduction. Additionally, after the in vivo knockdown of MeCP2, levels of MeCP2 protein, phospho-CREB, and phospho-mTOR were reduced compared to the placebo group. A reduced IgG deposition in the brain of the B6.Mecp2Tg1 mice were observed following treatment. Interestingly, behavioral functions and defects of the blood-brain barrier (BBB) were attenuated after spleen-targeted LNP-ASO treatment. Tissue-specific knockdown of a disease-promoting gene, MeCP2, via spleen-targeting LNPs effectively modulated the peripheral immune system resulting in subsequent amelioration of autoantibody production, inflammation, and behavioral deficits. These preclinical findings suggest that immunomodulation may be a promising therapeutic strategy for neuropsychiatric diseases.
- 31 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Open AccessImmunomodulation of behavior impairment via spleen-specific targeting lipid nanoparticles in a MeCP2 transgenic mouse model
This study investigates a novel approach using spleen-targeting lipid nanoparticles (LNPs) to immunomodulate behavioral impairment in a Methyl-CpG-binding protein 2 (Mecp2) transgenic mouse model. In a human Mecp2 transgenic mouse model (B6.Mecp2Tg1), spleen-targeting lipid nanoparticles encapsulated with antisense oligonucleotides (ASO) were employed as a mitigating agent. Splenic immune cells were analyzed using flow cytometry; autoantibody production was assessed using autoantigen protein microarrays, including a central nervous system (CNS) protein microarray. Furthermore, proinflammatory cytokines, MeCP2-mediated signaling pathways, and manifestations of behavior functions and kidney disease were examined. Our findings indicated a reduction in splenic MeCP2 levels following in vivo knockdown via ASO. Notably, splenic immune cells, including B and T cells, particularly plasma B cells, were significantly reduced after LNP-ASO treatment. Levels of autoantibodies against typical nuclear antigens such as Sm, U1-snRNP B/B, and nucleosome antigens, as well as brain antigens including OLIG2, GAD2, GJA1, and YWHAE, were significantly alleviated. Proinflammatory molecules such as IL-5, TNF-α, CCL20 and TGF-β1 showed significant reduction. Additionally, after the in vivo knockdown of MeCP2, levels of MeCP2 protein, phospho-CREB, and phospho-mTOR were reduced compared to the placebo group. A reduced IgG deposition in the brain of the B6.Mecp2Tg1 mice were observed following treatment. Interestingly, behavioral functions and defects of the blood-brain barrier (BBB) were attenuated after spleen-targeted LNP-ASO treatment. Tissue-specific knockdown of a disease-promoting gene, MeCP2, via spleen-targeting LNPs effectively modulated the peripheral immune system resulting in subsequent amelioration of autoantibody production, inflammation, and behavioral deficits. These preclinical findings suggest that immunomodulation may be a promising therapeutic strategy for neuropsychiatric diseases.
- Open Access
- 7 May 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (5) , e70044
Urinary V‐Set Ig Domain‐Containing Protein 4 and Immune Complexes for Tracking Lupus Nephritis and Renal Pathology
Objective: This study aims to investigate whether V‐set Ig domain‐containing protein 4 (VSIG4; also known as complement receptor of the Ig superfamily [CRIg]) forms immune complexes (ICxs) with IgG and complement component 3 (C3) in the kidneys of patients with lupus nephritis (LN) and to assess the potential of urinary VSIG4 and VSIG4‐ICx as noninvasive biomarkers of LN.Methods: Immunofluorescent staining was employed to detect the deposition of VSIG4 (CRIg), IgG, and C3 in kidney tissue. Urine samples from 102 patients with LN, 51 healthy controls (HCs), and 13 patients with chronic kidney disease (CKD) were analyzed via enzyme‐linked immunosorbent assay for VSIG4‐ICx and free‐form VSIG4.Results: Immunofluorescence costaining demonstrated the colocalization of VSIG4, IgG, and C3 in the kidneys of those with LN and elevated VSIG4 protein expression in the glomeruli regions in LN. Compared with HCs and those with CKD, patients with LN exhibited significantly elevated levels of urinary VSIG4 in both free form and ICx. Urinary VSIG4‐ICx correlated with clinical parameters, including the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (R = 0.55, P < 0.0001), renal SLEDAI (R = 0.52, P < 0.0001), estimated glomerular filtration rate (−0.5, P < 0.001), activity index (R = 0.25, P < 0.05), chronicity index (R = 0.32, P < 0.05), complement C3 (R = −0.33, P < 0.05), and complement C4 (R = −0.31, P < 0.05). The strong association of the urinary VSIG4‐ICx with disease activity metrics and histopathologic evidence underscores its potential for clinical utility in diagnosing and monitoring LN.Conclusion: VSIG4‐ICx shows promise as a novel urine biomarker for LN, with potential utility for diagnosis and disease monitoring. image
- 7 May 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (5) , e70044
Open AccessUrinary V‐Set Ig Domain‐Containing Protein 4 and Immune Complexes for Tracking Lupus Nephritis and Renal Pathology
Objective: This study aims to investigate whether V‐set Ig domain‐containing protein 4 (VSIG4; also known as complement receptor of the Ig superfamily [CRIg]) forms immune complexes (ICxs) with IgG and complement component 3 (C3) in the kidneys of patients with lupus nephritis (LN) and to assess the potential of urinary VSIG4 and VSIG4‐ICx as noninvasive biomarkers of LN.Methods: Immunofluorescent staining was employed to detect the deposition of VSIG4 (CRIg), IgG, and C3 in kidney tissue. Urine samples from 102 patients with LN, 51 healthy controls (HCs), and 13 patients with chronic kidney disease (CKD) were analyzed via enzyme‐linked immunosorbent assay for VSIG4‐ICx and free‐form VSIG4.Results: Immunofluorescence costaining demonstrated the colocalization of VSIG4, IgG, and C3 in the kidneys of those with LN and elevated VSIG4 protein expression in the glomeruli regions in LN. Compared with HCs and those with CKD, patients with LN exhibited significantly elevated levels of urinary VSIG4 in both free form and ICx. Urinary VSIG4‐ICx correlated with clinical parameters, including the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (R = 0.55, P < 0.0001), renal SLEDAI (R = 0.52, P < 0.0001), estimated glomerular filtration rate (−0.5, P < 0.001), activity index (R = 0.25, P < 0.05), chronicity index (R = 0.32, P < 0.05), complement C3 (R = −0.33, P < 0.05), and complement C4 (R = −0.31, P < 0.05). The strong association of the urinary VSIG4‐ICx with disease activity metrics and histopathologic evidence underscores its potential for clinical utility in diagnosing and monitoring LN.Conclusion: VSIG4‐ICx shows promise as a novel urine biomarker for LN, with potential utility for diagnosis and disease monitoring. image
- Open Access
- 1 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1541907
A serum biomarker panel and miniarray detection system for tracking disease activity and flare risk in lupus nephritis
Introduction: Lupus nephritis (LN) leads to end stage renal disease (ESRD), and early diagnosis and disease monitoring of LN could significantly reduce the risk. however, there is not such a system clinically. In this study we aim to develop a biomarker-panel based point-of-care system for LN.Methods: Immunoassay screening combined with genomic expression databases and machine learning techniques was used to identify a biomarker panel of LN. A quantitative biomarker-panel mini-array (BPMA) system was developed and the sensitivity, specificity, reproducibility, and stability of the were examined. The performance of BPMA in disease monitoring was validated with machine models using a larger cohort of LN. The BPMA was also used to determine LN flare using a machine-learning generated flare score (F-Score).Results: Among 32 promising LN serum biomarkers, VSIG4, TNFRSF1b, VCAM1, ALCAM, OPN, and IgG anti-dsDNA antibody were selected to constitute an LN biomarker Panel, which exhibited excellent discriminative value in distinguishing LN from healthy controls (AUC = 1.0) and active LN from inactive LN (AUC = 0.92), respectively. Also, the 6-biomarker panel exhibited a strong correlation with key clinical parameters of LN. A multiplexed immunoarray was constructed with the 6-biomarker panel (named BPMA-S6 thereafter). An LN-specific 8-point standard curve was generated for each protein biomarker. Cross-reaction between these biomarkers was minimal (< 1%). BPMA-S6 test results were highly correlated with those from ELISA (Spearman’s correlation: fluorescent detection, rs = 0.95; colorimetric detection, rs = 0.91). The discriminative value of BPMA-S6 for LN was further validated using an independent cohort (AUC = 0.94). Using a longitudinal cohort of LN, the derived F-Score exhibited superior discriminative value in the training dataset (AUC = 0.92) and testing dataset (AUC=0.82) to distinguish flare vs remission.Conclusion: BPMA-S6 may represent a promising point-of-care test (POCT) for the diagnosis, disease monitoring, and assessment of LN flare.
- 1 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1541907
Open AccessA serum biomarker panel and miniarray detection system for tracking disease activity and flare risk in lupus nephritis
Introduction: Lupus nephritis (LN) leads to end stage renal disease (ESRD), and early diagnosis and disease monitoring of LN could significantly reduce the risk. however, there is not such a system clinically. In this study we aim to develop a biomarker-panel based point-of-care system for LN.Methods: Immunoassay screening combined with genomic expression databases and machine learning techniques was used to identify a biomarker panel of LN. A quantitative biomarker-panel mini-array (BPMA) system was developed and the sensitivity, specificity, reproducibility, and stability of the were examined. The performance of BPMA in disease monitoring was validated with machine models using a larger cohort of LN. The BPMA was also used to determine LN flare using a machine-learning generated flare score (F-Score).Results: Among 32 promising LN serum biomarkers, VSIG4, TNFRSF1b, VCAM1, ALCAM, OPN, and IgG anti-dsDNA antibody were selected to constitute an LN biomarker Panel, which exhibited excellent discriminative value in distinguishing LN from healthy controls (AUC = 1.0) and active LN from inactive LN (AUC = 0.92), respectively. Also, the 6-biomarker panel exhibited a strong correlation with key clinical parameters of LN. A multiplexed immunoarray was constructed with the 6-biomarker panel (named BPMA-S6 thereafter). An LN-specific 8-point standard curve was generated for each protein biomarker. Cross-reaction between these biomarkers was minimal (< 1%). BPMA-S6 test results were highly correlated with those from ELISA (Spearman’s correlation: fluorescent detection, rs = 0.95; colorimetric detection, rs = 0.91). The discriminative value of BPMA-S6 for LN was further validated using an independent cohort (AUC = 0.94). Using a longitudinal cohort of LN, the derived F-Score exhibited superior discriminative value in the training dataset (AUC = 0.92) and testing dataset (AUC=0.82) to distinguish flare vs remission.Conclusion: BPMA-S6 may represent a promising point-of-care test (POCT) for the diagnosis, disease monitoring, and assessment of LN flare.
- 21 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (2) , 453-463
V-set and immunoglobulin domain containing 4 as a potential predictor of Alzheimer's disease and advanced aging
Background: V-set and immunoglobulin domain containing 4 (VSIG4) emerges as a significant player in the immune system pathways. It has been previously identified as a potential hub gene for Alzheimer's disease (AD) and aging, underscoring its importance in understanding these conditions. Objective: This study aimed to evaluate the diagnostic potential of serum VSIG4 and identify trends in serum VSIG4 in relationship with other biomarkers and neurological tests. Methods: ELISA was used to measure the serum concentration of VSIG4 in AD, compared to healthy subjects. The relationship between VSIG4 levels and the age of the subjects, as well as other AD-related serum proteins and various measures of cognition was examined. Results: VSIG4 was significantly elevated in the serum of AD patients compared to healthy controls (p = 0.0074). Significant correlations were identified between serum VSIG4 and other notable proteins related to AD and inflammation, such as total tau, neurofilament light (NfL), YKL-40, CD14, FABP3, and TNF-α. Significant correlations were also identified between VSIG4 concentration and the results of neurological tests. Conclusions: Serum VSIG4 may reflect neuroinflammation and altered lipid processing, affecting the cognitive performance of AD and aging.
- 21 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (2) , 453-463
V-set and immunoglobulin domain containing 4 as a potential predictor of Alzheimer's disease and advanced aging
Background: V-set and immunoglobulin domain containing 4 (VSIG4) emerges as a significant player in the immune system pathways. It has been previously identified as a potential hub gene for Alzheimer's disease (AD) and aging, underscoring its importance in understanding these conditions. Objective: This study aimed to evaluate the diagnostic potential of serum VSIG4 and identify trends in serum VSIG4 in relationship with other biomarkers and neurological tests. Methods: ELISA was used to measure the serum concentration of VSIG4 in AD, compared to healthy subjects. The relationship between VSIG4 levels and the age of the subjects, as well as other AD-related serum proteins and various measures of cognition was examined. Results: VSIG4 was significantly elevated in the serum of AD patients compared to healthy controls (p = 0.0074). Significant correlations were identified between serum VSIG4 and other notable proteins related to AD and inflammation, such as total tau, neurofilament light (NfL), YKL-40, CD14, FABP3, and TNF-α. Significant correlations were also identified between VSIG4 concentration and the results of neurological tests. Conclusions: Serum VSIG4 may reflect neuroinflammation and altered lipid processing, affecting the cognitive performance of AD and aging.
- Open Access
- 29 January 2025
- Published by MDPI AG in Micromachines
- Vol. 16 (2) , 156
Portable Fluorescence Microarray Reader-Enabled Biomarker Panel Detection System for Point-of-Care Diagnosis of Lupus Nephritis
Point-of-care (POC) testing has revolutionized diagnostics by providing rapid, accessible solutions outside traditional laboratory settings. However, many POC systems lack the sensitivity or multiplexing capability required for complex diseases. This study introduces an LED-based fluorescence reader designed for POC applications, enabling multiplex detection of lupus nephritis (LN) biomarkers using a biomarker microarray (BMA) slide. The reader integrates an LED excitation source, neutral density (ND) filters for precise intensity control, and onboard image processing with Gaussian smoothing and centroid thresholding to enhance signal detection and localization. Five LN biomarkers (VSIG4, OPN, VCAM1, ALCAM, and TNFRSF1B) were assessed, and performance was validated against a Genepix laser-based scanner. The LED reader demonstrated strong correlation coefficients (r = 0.96–0.98) with the Genepix system for both standard curves and patient samples, achieving robust signal-to-noise ratios and reproducibility across all biomarkers. The multiplex format reduced sample volume and allowed simultaneous analysis of multiple biomarkers. These results highlight the reader’s potential to bridge the gap between laboratory-grade precision and POC accessibility. By combining portability, cost-effectiveness, and high analytical performance, this fluorescence reader provides a practical solution for POC diagnostics, particularly in resource-limited settings, improving the feasibility of routine monitoring and early intervention for diseases requiring comprehensive biomarker analysis.
- 29 January 2025
- Published by MDPI AG in Micromachines
- Vol. 16 (2) , 156
Open AccessPortable Fluorescence Microarray Reader-Enabled Biomarker Panel Detection System for Point-of-Care Diagnosis of Lupus Nephritis
Point-of-care (POC) testing has revolutionized diagnostics by providing rapid, accessible solutions outside traditional laboratory settings. However, many POC systems lack the sensitivity or multiplexing capability required for complex diseases. This study introduces an LED-based fluorescence reader designed for POC applications, enabling multiplex detection of lupus nephritis (LN) biomarkers using a biomarker microarray (BMA) slide. The reader integrates an LED excitation source, neutral density (ND) filters for precise intensity control, and onboard image processing with Gaussian smoothing and centroid thresholding to enhance signal detection and localization. Five LN biomarkers (VSIG4, OPN, VCAM1, ALCAM, and TNFRSF1B) were assessed, and performance was validated against a Genepix laser-based scanner. The LED reader demonstrated strong correlation coefficients (r = 0.96–0.98) with the Genepix system for both standard curves and patient samples, achieving robust signal-to-noise ratios and reproducibility across all biomarkers. The multiplex format reduced sample volume and allowed simultaneous analysis of multiple biomarkers. These results highlight the reader’s potential to bridge the gap between laboratory-grade precision and POC accessibility. By combining portability, cost-effectiveness, and high analytical performance, this fluorescence reader provides a practical solution for POC diagnostics, particularly in resource-limited settings, improving the feasibility of routine monitoring and early intervention for diseases requiring comprehensive biomarker analysis.
- Open Access
- 12 December 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (24) , 2787
Urinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis
Background/Objectives: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), involving immune complex deposition in the kidneys. While renal biopsy is the diagnostic gold standard, its invasiveness limits frequent use, driving the need for non-invasive urinary biomarkers to monitor disease progression and response to treatment. This study aimed to identify and validate urinary biomarkers for LN. Methods: Data from 10 LN-related omics databases, including urine, PBMCs, and kidney tissue, were analyzed. Differentially expressed proteins (DEPs) and genes (DEGs) were identified, and candidate biomarkers were validated via ELISA in an independent cohort of 87 urine samples. Results: We identified 78 biomarkers, with 14 overlapping across transcriptomic categories. Novel urinary biomarkers, including SERPING1, SLPI, and CD48, were validated. Urinary CD163, VCAM1, and ALCAM levels showed significant differences between LN and healthy controls, while urinary immune complexes (ICx) demonstrated superior diagnostic performance, with urinary ALCAM-ICx and CCL21-ICx achieving the highest AUC values. Conclusions: Our findings highlight the potential of urinary immune complexes and antigens as non-invasive biomarkers for LN. ALCAM, CD163, and SERPING1-ICx, in particular, were found as promising candidates for a urinary biomarker panel to aid in the diagnosis and monitoring of LN.
- 12 December 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (24) , 2787
Open AccessUrinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis
Background/Objectives: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), involving immune complex deposition in the kidneys. While renal biopsy is the diagnostic gold standard, its invasiveness limits frequent use, driving the need for non-invasive urinary biomarkers to monitor disease progression and response to treatment. This study aimed to identify and validate urinary biomarkers for LN. Methods: Data from 10 LN-related omics databases, including urine, PBMCs, and kidney tissue, were analyzed. Differentially expressed proteins (DEPs) and genes (DEGs) were identified, and candidate biomarkers were validated via ELISA in an independent cohort of 87 urine samples. Results: We identified 78 biomarkers, with 14 overlapping across transcriptomic categories. Novel urinary biomarkers, including SERPING1, SLPI, and CD48, were validated. Urinary CD163, VCAM1, and ALCAM levels showed significant differences between LN and healthy controls, while urinary immune complexes (ICx) demonstrated superior diagnostic performance, with urinary ALCAM-ICx and CCL21-ICx achieving the highest AUC values. Conclusions: Our findings highlight the potential of urinary immune complexes and antigens as non-invasive biomarkers for LN. ALCAM, CD163, and SERPING1-ICx, in particular, were found as promising candidates for a urinary biomarker panel to aid in the diagnosis and monitoring of LN.
- Open Access
- 18 March 2024
- Published by MDPI AG in Biosensors
- Vol. 14 (3) , 147
Advancing Point-of-Care Diagnosis: Digitalizing Combinatorial Biomarker Signals for Lupus Nephritis
To improve the efficiency and patient coverage of the current healthcare system, user-friendly novel homecare devices are urgently needed. In this work, we developed a smartphone-based analyzing and reporting system (SBARS) for biomarker detection in lupus nephritis (LN). This system offers a cost-effective alternative to traditional, expensive large equipment in signal detection and quantification. This innovative approach involves using a portable and affordable microscopic reader to capture biomarker signals. Through smartphone-based image processing techniques, the intensity of each biomarker signal is analyzed. This system exhibited comparable performance to a commercial Genepix scanner in the detection of two potential novel biomarkers of LN, VISG4 and TNFRSF1b. Importantly, this smartphone-based analyzing and reporting system allows for discriminating LN patients with active renal disease from healthy controls with the area-under-the-curve (AUC) value = 0.9 for TNFRSF1b and 1.0 for VSIG4, respectively, indicating high predictive accuracy.
- 18 March 2024
- Published by MDPI AG in Biosensors
- Vol. 14 (3) , 147
Open AccessAdvancing Point-of-Care Diagnosis: Digitalizing Combinatorial Biomarker Signals for Lupus Nephritis
To improve the efficiency and patient coverage of the current healthcare system, user-friendly novel homecare devices are urgently needed. In this work, we developed a smartphone-based analyzing and reporting system (SBARS) for biomarker detection in lupus nephritis (LN). This system offers a cost-effective alternative to traditional, expensive large equipment in signal detection and quantification. This innovative approach involves using a portable and affordable microscopic reader to capture biomarker signals. Through smartphone-based image processing techniques, the intensity of each biomarker signal is analyzed. This system exhibited comparable performance to a commercial Genepix scanner in the detection of two potential novel biomarkers of LN, VISG4 and TNFRSF1b. Importantly, this smartphone-based analyzing and reporting system allows for discriminating LN patients with active renal disease from healthy controls with the area-under-the-curve (AUC) value = 0.9 for TNFRSF1b and 1.0 for VSIG4, respectively, indicating high predictive accuracy.
- Open Access
- 8 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1370254
Autoimmune and neuropsychiatric phenotypes in a Mecp2 transgenic mouse model on C57BL/6 background
Introduction: Systemic Lupus Erythematosus (SLE) impacts the central nervous system (CNS), leading to severe neurological and psychiatric manifestations known as neuropsychiatric lupus (NPSLE). The complexity and heterogeneity of clinical presentations of NPSLE impede direct investigation of disease etiology in patients. The limitations of existing mouse models developed for NPSLE obstruct a comprehensive understanding of this disease. Hence, the identification of a robust mouse model of NPSLE is desirable.Methods: C57BL/6 mice transgenic for human MeCP2 (B6.Mecp2Tg1) were phenotyped, including autoantibody profiling through antigen array, analysis of cellularity and activation of splenic immune cells through flow cytometry, and measurement of proteinuria. Behavioral tests were conducted to explore their neuropsychiatric functions. Immunofluorescence analyses were used to reveal altered neurogenesis and brain inflammation. Various signaling molecules implicated in lupus pathogenesis were examined using western blotting.Results: B6.Mecp2Tg1 exhibits elevated proteinuria and an overall increase in autoantibodies, particularly in female B6.Mecp2Tg1 mice. An increase in CD3+CD4+ T cells in the transgenic mice was observed, along with activated germinal center cells and activated CD11b+F4/80+ macrophages. Moreover, the transgenic mice displayed reduced locomotor activity, heightened anxiety and depression, and impaired short-term memory. Immunofluorescence analysis revealed IgG deposition and immune cell infiltration in the kidneys and brains of transgenic mice, as well as altered neurogenesis, activated microglia, and compromised blood-brain barrier (BBB). Additionally, protein levels of various key signaling molecules were found to be differentially modulated upon MeCP2 overexpression, including GFAP, BDNF, Albumin, NCoR1, mTOR, and NLRP3.Discussion: Collectively, this work demonstrates that B6.Mecp2Tg1 mice exhibit lupus-like phenotypes as well as robust CNS dysfunctions, suggesting its utility as a new animal model for NPSLE.
- 8 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1370254
Open AccessAutoimmune and neuropsychiatric phenotypes in a Mecp2 transgenic mouse model on C57BL/6 background
Introduction: Systemic Lupus Erythematosus (SLE) impacts the central nervous system (CNS), leading to severe neurological and psychiatric manifestations known as neuropsychiatric lupus (NPSLE). The complexity and heterogeneity of clinical presentations of NPSLE impede direct investigation of disease etiology in patients. The limitations of existing mouse models developed for NPSLE obstruct a comprehensive understanding of this disease. Hence, the identification of a robust mouse model of NPSLE is desirable.Methods: C57BL/6 mice transgenic for human MeCP2 (B6.Mecp2Tg1) were phenotyped, including autoantibody profiling through antigen array, analysis of cellularity and activation of splenic immune cells through flow cytometry, and measurement of proteinuria. Behavioral tests were conducted to explore their neuropsychiatric functions. Immunofluorescence analyses were used to reveal altered neurogenesis and brain inflammation. Various signaling molecules implicated in lupus pathogenesis were examined using western blotting.Results: B6.Mecp2Tg1 exhibits elevated proteinuria and an overall increase in autoantibodies, particularly in female B6.Mecp2Tg1 mice. An increase in CD3+CD4+ T cells in the transgenic mice was observed, along with activated germinal center cells and activated CD11b+F4/80+ macrophages. Moreover, the transgenic mice displayed reduced locomotor activity, heightened anxiety and depression, and impaired short-term memory. Immunofluorescence analysis revealed IgG deposition and immune cell infiltration in the kidneys and brains of transgenic mice, as well as altered neurogenesis, activated microglia, and compromised blood-brain barrier (BBB). Additionally, protein levels of various key signaling molecules were found to be differentially modulated upon MeCP2 overexpression, including GFAP, BDNF, Albumin, NCoR1, mTOR, and NLRP3.Discussion: Collectively, this work demonstrates that B6.Mecp2Tg1 mice exhibit lupus-like phenotypes as well as robust CNS dysfunctions, suggesting its utility as a new animal model for NPSLE.